Aspen Neuroscience, a clinical-stage regenerative medicine company developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with ...
WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (VIGL) (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the ...
– Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control – – ALTO-203, a non-stimulant compound ...
– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated ...
(RTTNews) - Vigil Neuroscience (VIGL) reported positive data from completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of Alzheimers disease. The company said, collectively, ...
Traumatic brain injury is a leading cause of death and disability Currently, there is no treatment to prevent the long-term effects of traumatic brain injury Findings could translate into treating ...
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results